Exicure

company

About

Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets.

  • 1 - 10

Details

Last Funding Type
Series Unknown
Last Funding Money Raised
$20M
Industries
Biotechnology,Genetics,Life Science,Therapeutics
Founded date
Jan 1, 2009
Number Of Employee
1 - 10
Operating Status
Active

Exicure is Formerly Known as AuraSense Therapeuticsis. Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets. Our 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Our lead programs address diseases from inflammatory disorders to oncology.

SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. SNA constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. Moreover, SNAs can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
4
$51.39M
Exicure has raised a total of $51.39M in funding over 2 rounds. Their latest funding was raised on Nov 6, 2017 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Nov 6, 2017 Series Unknown $11.20M 1 Detail
Sep 27, 2017 Series Unknown $20M 2 Detail
Oct 21, 2015 Series Unknown $14.79M 1 Detail
Dec 21, 2011 Series B $5.40M 1 Detail

Investors

Number of Lead Investors
Number of Investors
4
Exicure is funded by 4 investors. Knoll Capital Management and Tempus are the most recent investors.
Investor Name Lead Investor Funding Round
Knoll Capital Management Series Unknown
Tempus Series Unknown
Katalyst Securities Series Unknown
Abbott Biotech Ventures Series B